Ceftazidime/avibactam (bacterial infections, several therapeutic indications, from birth to < 3 months) – Assessment according to §35a (para. 1c) Social Code Book V

Report documents

1. Dossier assessment

   Ceftazidime/avibactam (bacterial infections, several therapeutic indications, from birth to < 3 months) – Assessment according to §35a (para. 1c) Social Code Book V

   published on

   15.04.2025

   Document type

   PDF document, 379 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G24-34_V1.1

   Download file : Dossier assessment (PDF document, 379 kB, DE, not accessible)

Project details

Project no.

G24-34

Commission

Commission awarded on 18.11.2024 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Health Economics

Topic

Immune system and infections

Note

In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on Feb 20, 2025.

DOI

https://doi.org/10.60584/G24-34_V1.1

Connected Projects

1. Dossier assessment

   Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V

   Project no.

   G22-16

   Last updated

   15.08.2022

   Status: Commission completed